Tandem Diabetes Q3 sales $179.6M (+45% YoY); raises FY2021 sales guidance to $685-695M

TANDEM DIABETES CARE INC

2021-Q3 EPS reported $0.07 revenue$492,803,000

Q3 sales $179.6M (+45% YoY); net income $5.8M vs loss $9.4M; adjusted EBITDA $26.9M (15% of sales).
Worldwide pump shipments up 43% to 31,558; international shipments up 209% to 11,262.
Full-year 2021 sales guidance raised to $685-695M from $670-685M; international guidance raised to $168-173M.
Cash balance $595M, up $110M since Dec 2020; gross margin improved to 54% from 53%.
Virtual R&D Day scheduled for December 6, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.